Levy Gilberto
Department of Biostatistics, Columbia University, 722 W 168th St, Sixth Floor, New York, NY 10032, USA.
Arch Neurol. 2007 Sep;64(9):1242-6. doi: 10.1001/archneur.64.9.1242.
Twentieth-century hypotheses attributing a substantive role to aging in Parkinson disease (PD) pathogenesis have been countered by evidence from clinical, pathological, and biochemical investigations. However, age influences the clinical progression of PD. Several studies have demonstrated that advancing age is associated with a faster rate of motor progression, decreased levodopa responsiveness, more severe gait and postural impairment, and more severe cognitive impairment and the development of dementia in patients with PD. A model for the relationship between PD and aging is proposed that incorporates the following 3 elements: (1) There occurs a superposition of a topographic gradient of neuronal loss in brainstem and basal forebrain structures related to the disease process and an aging-related temporal gradient. (2) While PD is a chronic progressive disorder, the most important determinant of clinical progression is advancing age rather than disease duration. (3) The effects of the disease process and aging on nondopaminergic structures involve a biologic interaction. The model implies that understanding the degenerative process in nondopaminergic structures in PD as it relates to molecular mechanisms accompanying the aging of the nervous system may create opportunities for interventions affecting the clinical progression of the disease.
20世纪关于衰老在帕金森病(PD)发病机制中起重要作用的假说,已遭到临床、病理及生化研究证据的反驳。然而,年龄会影响PD的临床进展。多项研究表明,年龄增长与运动进展速度加快、左旋多巴反应性降低、步态和姿势障碍更严重、认知障碍更严重以及PD患者痴呆的发生有关。本文提出了一个PD与衰老关系的模型,该模型包含以下三个要素:(1)与疾病过程相关的脑干和基底前脑结构中神经元丢失的地形梯度与衰老相关的时间梯度发生叠加。(2)虽然PD是一种慢性进行性疾病,但临床进展的最重要决定因素是年龄增长而非病程。(3)疾病过程和衰老对非多巴胺能结构的影响涉及生物相互作用。该模型表明,了解PD中非多巴胺能结构的退行性过程,因为它与神经系统衰老伴随的分子机制相关,可能为影响疾病临床进展的干预创造机会。